PMID- 36013595
OWN - NLM
STAT- MEDLINE
DCOM- 20220829
LR  - 20230308
IS  - 1648-9144 (Electronic)
IS  - 1010-660X (Print)
IS  - 1010-660X (Linking)
VI  - 58
IP  - 8
DP  - 2022 Aug 19
TI  - Effects of Sodium-Glucose Co-Transporter-2 Inhibition on Pulmonary Arterial 
      Stiffness and Right Ventricular Function in Heart Failure with Reduced Ejection 
      Fraction.
LID - 10.3390/medicina58081128 [doi]
LID - 1128
AB  - Background and Objectives: In addition to left ventricular (LV) functions, right 
      ventricular (RV) functions and pulmonary arterial stiffness (PAS) may be 
      adversely affected in patients with heart failure with reduced ejection fraction 
      (HFrEF). Sodium-glucose co-transporter-2 (SGLT2) inhibitor therapy positively 
      affects LV functions as well as having functional and symptomatic benefits in 
      HFrEF patients. In this study, we aimed to evaluate the effects of SGLT2 
      inhibitor treatment on RV function and PAS in HFrEF patients. Materials 
      andMethods: 168 HFrEF patients with New York Heart Association (NYHA) class >/=2 
      symptoms despite optimal medical treatment and who were started on SGLT2 
      inhibitor therapy were included in this retrospective study. NYHA classification, 
      N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, Minnesota Living 
      with Heart Failure Questionnaire (MLWHFQ) scores, laboratory tests, and 
      transthoracic echocardiography (TTE) measurements were recorded before treatment 
      and at the end of the 6-month follow-up. Results: The mean age of the patients 
      was 62.7 +/- 11.4 years, and 38 (22.6%) were women. RV function (RV fractional area 
      change (FAC) (33.8 +/- 6.4% vs. 39.2 +/- 7.3%, p < 0.001); tricuspid annular plane 
      systolic excursion (TAPSE) (18.4 +/- 3.8 mm vs. 19.6 +/- 3.6 mm, p < 0.001); RV S' 
      (10 (8 - 13) cm/s vs. 13 (10 - 16) cm/s, p < 0.001); RV myocardial performance 
      index (RV MPI) (0.68 +/- 0.12 vs. 0.59 +/- 0.11, p < 0.001); mean pulmonary artery 
      pressure (mPAP) (39.6 +/- 7.8 mmHg vs. 32 +/- 6.8 mmHg, p = 0.003)) and PAS (24.2 +/- 
      4.6 kHz/ms vs. 18.6 +/- 3.1 kHz/ms, p < 0.001) values at the 6-month follow-up 
      after SGLT2 inhibitor therapy significantly improved. It was found that SGLT2 
      inhibitor treatment provided significant improvement in NYHA classification, 
      MLWHFQ scores, and NT-proBNP levels (2876 +/- 401 vs. 1034 +/- 361, p < 0.001), and 
      these functional and symptomatic positive changes in HFrEF patients were 
      significantly correlated with positive changes in LVEF, PAS, and RV functional 
      status. Conclusions: SGLT2 inhibitor treatment results in symptomatic and 
      functional well-being in HFrEF patients, as well as positive changes in RV 
      function and PAS.
FAU - Camci, Sencer
AU  - Camci S
AUID- ORCID: 0000-0003-2152-0470
AD  - Department of Cardiology, Faculty of Medicine, Giresun University, 28100 Giresun, 
      Turkey.
FAU - Yilmaz, Emre
AU  - Yilmaz E
AD  - Department of Cardiology, Faculty of Medicine, Giresun University, 28100 Giresun, 
      Turkey.
LA  - eng
PT  - Journal Article
DEP - 20220819
PL  - Switzerland
TA  - Medicina (Kaunas)
JT  - Medicina (Kaunas, Lithuania)
JID - 9425208
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 9NEZ333N27 (Sodium)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Aged
MH  - Female
MH  - Glucose
MH  - *Heart Failure
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Pulmonary Artery
MH  - Retrospective Studies
MH  - Sodium
MH  - Sodium-Glucose Transporter 2
MH  - *Sodium-Glucose Transporter 2 Inhibitors/pharmacology/therapeutic use
MH  - Stroke Volume/physiology
MH  - *Vascular Stiffness
MH  - *Ventricular Dysfunction, Left
MH  - *Ventricular Dysfunction, Right/drug therapy
MH  - Ventricular Function, Right/physiology
PMC - PMC9415977
OTO - NOTNLM
OT  - SGLT2 inhibitors
OT  - heart failure
OT  - pulmonary arterial stiffness
OT  - right ventricular function
COIS- The authors declare no conflict of interest.
EDAT- 2022/08/27 06:00
MHDA- 2022/08/30 06:00
PMCR- 2022/08/19
CRDT- 2022/08/26 01:30
PHST- 2022/07/24 00:00 [received]
PHST- 2022/08/08 00:00 [revised]
PHST- 2022/08/15 00:00 [accepted]
PHST- 2022/08/26 01:30 [entrez]
PHST- 2022/08/27 06:00 [pubmed]
PHST- 2022/08/30 06:00 [medline]
PHST- 2022/08/19 00:00 [pmc-release]
AID - medicina58081128 [pii]
AID - medicina-58-01128 [pii]
AID - 10.3390/medicina58081128 [doi]
PST - epublish
SO  - Medicina (Kaunas). 2022 Aug 19;58(8):1128. doi: 10.3390/medicina58081128.